Interactions of the fungal pathogen Candida albicans with the host

Future Microbiology

Volumn 2, Issue 2, 2007, Pages 141-151

  Rupp, Steffen ^a  

^a FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB   (Germany)

Author keywords

Antibody mediated immunity; Candidiasis; Commensal; Host pathogen interaction; Medical mycology; Pathogen; Vaccines

Indexed keywords

ADHESIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CELL SURFACE PROTEIN; DIPHTHERIA TOXOID; ECHINOCANDIN; FLUCONAZOLE; KETOCONAZOLE; LAMINARAN; MYCOGRAB; PLACEBO; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EFG1; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBODY RESPONSE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; CELL SURFACE; CLINICAL TRIAL; COMMENSALISM; DISEASE MODEL; EPITHELIUM CELL; FUNGAL COLONIZATION; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS HYPHAE; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOPROPHYLAXIS; INFECTION RISK; INTENSIVE CARE UNIT; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THRUSH; TRANSCRIPTOMICS;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; HUMANS; MICROSCOPY, ELECTRON, SCANNING;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; FUNGI;

EID: 34248665821     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.2.141     Document Type: Review

References (90)

1. Latge JP, Calderone R: Host-microbe interactions: fungi invasive human fungal opportunistic infections. Curr. Opin. Microbiol. 5, 355-358 (2002).
2. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn. Microbiol. Infect. Dis. 30, 121-129 (1998).
3. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R: Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27, 359-366 (2006).
4. Francois IE, Aerts AM, Cammue BP, Thevissen K: Currently used antimycotics: spectrum, mode of action and resistance occurrence. Curr. Drug Targets 6, 895-907 (2005).
5. Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2, 73-85 (2002).
6. Rex JH, Walsh TJ, Sobel JD et al.: Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 662-678 (2000).
7. Calderone RA (Ed.): Candida and Candidiasis. ASM Press, Washington, DC, USA (2002).
8. Poulain D, Jouault T: Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Curr. Opin. Microbiol. 7, 342-349 (2004).
9. Klis FM, de Groot P, Hellingwerf K: Molecular organization of the cell wall of Candida albicans. Med. Mycol. 39, 1-8 (2001).
10. Ruiz-Herrera J, Elorza MV, Valentin E, Sentandreu R: Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS Yeast Res. 6, 14-29 (2006).
11. Klis FM, Boorsma A, De Groot PW: Cell wall construction in Saccharomyres cerevisiae. Yeast 23, 185-202 (2006).
12. Sohn K, Schwenk J, Urban C, Lechner J, Schweikert M, Rupp S: Getting in touch with Candida albicans: the cell wall of a fungal pathogen. Curr. Drug Targets 7, 505-512 (2006).
13. Onishi J, Meinz M, Thompson J et al.: Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 44, 368-377 (2000).
14. Pachl J, Svoboda P, Jacobs F et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42, 1404-1413 (2006).
15. Burnie JP, Carter TL, Hodgetts SJ, Matthews RC: Fungal heat-shock proteins in human disease. FEMS Microbiol. Rev. 30, 53-88 (2006).
16. Casadevall A, Pirofski LA: Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67, 3703-3713 (1999).
17. Casadevall A, Pirofski L: Host-pathogen interactions: the attributes of virulence. J. Infect. Dis. 184, 337-344 (2001).
18. Taylor BN, Harrer T, Pscheidl E, Schweizer A, Rollinghoff M, Schroppel K: Surveillance of nosocomial transmission of Candida albicans in an intensive care unit by DNA fingerprinting. J. Hosp. Infect. 55, 283-289 (2003).
19. Fonzi WA, Irwin MY: Isogenic strain construction and gene mapping in Candida albicans. Genetics 134, 717-728 (1993).
20. Liu H: Transcriptional control of dimorphism in Candida albicans. Curr. Opin. Microbiol. 4, 728-735 (2001).
21. Berman J, Sudbery PE: Candida albicans: a molecular revolution built on lessons from budding yeast. Nat. Rev. Genet. 3, 918-930 (2002).
22. Bruno VM, Mitchell AP: Large-scale gene function analysis in Candida albicans. Trends Microbiol. 12, 157-161 (2004).
23. Roemer T, Jiang B, Davison J et al.: Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol. Microbiol. 50, 167-181 (2003).
24. Kimura LH, Pearsall NN: Adherence of Candida albicans to human buccal epithelial cells. Infect. Immun. 21, 64-68 (1978).
25. Rotrosen D, Edwards JE Jr, Gibson TR, Moore JC, Cohen AH, Green I: Adherence of Candida to cultured vascular endothelial cells: mechanisms of attachment and endothelial cell penetration. J. Infect. Dis. 152, 1264-1274 (1985).
26. Korting HC, Patzak U, Schaller M, Maibach HI: A model of human cutaneous candidosis based on reconstructed human epidermis for the light and electron microscopic study of pathogenesis and treatment. J. Infect. 36, 259-267 (1998).
27. Filler SG, Swerdloff JN, Hobbs C, Luckett PM: Penetration and damage of endothelial cells by Candida albicans. Infect. Immun. 63, 976-983 (1995).
28. Dieterich C, Schandar M, Noll M et al.: In vitro reconstructed human epithelia reveal contributions of Candida albicans EFG1 and CPH1 to adhesion and invasion. Microbiology 148, 497-506 (2002).
29. King RD, Lee JC, Morris AL: Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect. Immun. 27, 667-674 (1980).
30. Fradin C, Kretschmar M, Nichterlein T, Gaillardin C, d'Enfert C, Hube B: Stage-specific gene expression of Candida albicans in human blood. Mol. Microbiol. 47, 1523-1543 (2003).
31. Zink S, Nass T, Rosen P, Ernst JF: Migration of the fungal pathogen Candida albicans across endothelial monolayers. Infect. Immun. 64, 5085-5091 (1996).
32. Jong AY, Stins MF, Huang SH, Chen SH, Kim KS: Traversal of Candida albicans across human blood-brain barrier in vitro. Infect. Immun. 69, 4536-4544 (2001).
33. Schaller M, Bein M, Korting HC et al.: The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect. Immun. 71, 3227-3234 (2003).
34. Rouabhia M, Schaller M, Corbucci C et al.: Virulence of the fungal pathogen Candida albicans requires the five isoforms of protein mannosyltransferases. Infect. Immun. 73, 4571-4580 (2005).
35. Naglik JR, Challacombe SJ, Hube B: Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev. 67, 400-428 (2003).
36. Schaller M, Borelli C, Korting HC, Hobe B: Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 48, 365-377 (2005).
37. Phan QT, Belanger PH, Filler SG: Role of hyphal formation in interactions of Candida albicans with endothelial cells. Infect. Immun. 68, 3485-3490 (2000).
38. Sohn K, Urban C, Brunner H, Rupp S: EFG1 is a major regulator of cell wall dynamics in Candida albicans as shown by DNA-microarrays. Mol. Microbiol. 47, 89-102 (2003).
39. Nomanbhoy F, Steele C, Yano J, Fidel PL Jr: Vaginal and oral epithelial cell anti-Candida activity. Infect. Immun. 70, 7081-7088 (2002).
40. Barousse MM, Espinosa T, Dunlap K, Fidel PL Jr: Vaginal epithelial cell anti-Candida albicans activity is associated with protection against symptomatic vaginal candidiasis. Infect. Immun. 73, 7765-7767 (2005).
41. Li XS, Reddy MS, Baev D, Edgerton M: Candida albicans Ssa 1/2p is the cell envelope binding protein for human salivary histatin 5. J. Biol. Chem. 278, 28553-28561 (2003).
42. Schaller M, Boeld U, Oberbauer S, Hamm G, Hube B, Korting HC: Polymorphonuclear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an in vitro model of oral candidosis. Microbiology 150, 2807-2813 (2004).
43. Crowe JD, Sievwright IK, Auld GC, Moore NR, Gow NA, Booth NA: Candida albicans binds human plasminogen: identification of eight plasminogen-binding proteins. Mol. Microbiol. 47, 1637-1651 (2003).
44. Jeffery CJ: Moonlighting proteins. Trends Biochem. Sci. 24, 8-11 (1999).
45. Pitarch A, Sanchez M, Nombela C, Gil C: Sequential fractionation and two-dimensional gel analysis unravels the complexity of the dimorphic fungus Candida albicans cell wall proteome. Mol. Cell. Proteomics 1, 967-982 (2002).
46. Urban C, Sohn K, Lottspeich F, Brunner H, Rupp S: Identification of surface determinants in C. albicans reveals Tsa1p, a protein differentially localized in the cell. FEBS Lett. 544, 229-236 (2003).
47. Chaffin WL, Lopez-Ribot JL, Casanova M, Gozalbo D, Martinez JP: Cell wall and secreted proteins of Candida albicans identification, function, and expression. Microbiol. Mol. Biol. Rev. 62, 130-180 (1998).
48. Gaur NK, Klotz SA: Expression, cloning, and characterization of a Candida albicans gene, ALA1, that confers adherence properties upon Saccharomyces cerevisiae for extracellular matrix proteins. Infect. Immun. 65, 5289-5294 (1997).
49. Gaur NK, Smith RL, Klotz SA: Candida albicans and Saccharomyces cerevisiae expressing ALA1/ALS5 adhere to accessible threonine, serine, or alanine patches. Cell Commun. Adhes. 9, 45-57 (2002).
50. Fu Y, Rieg G, Fonzi WA, Belanger PH, Edwards JE Jr, Filler SG: Expression of the Candida albicans gene ALS1 in Saccharomyces cerevisiae induces adherence to endothelial and epithelial cells. Infect. Immun. 66, 1783-1786 (1998).
51. Staab JF, Bradway SD, Fidel PL, Sundstrom P: Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science 283, 1535-1538 (1999).
52. Staab JF, Bahn YS, Thai CH, Cook PF, Sundstrom P: Expression of transglutaminase substrate activity on Candida albicans germ tubes through a coiled, disulfide-bonded N-terminal domain of Hwp1 requires C-terminal glycosylphosphatidylinositol modification. J. Biol. Chem. 279(39), 40737-40747 (2004).
53. Tsuchimori N, Sharkey LL, Fonzi WA, French SW, Edwards JE Jr, Filler SG: Reduced virulence of HWP1-deficient mutants of Candida albicans and their interactions with host cells. Infect. Immun. 68, 1997-2002 (2000).
54. Sharkey LL, McNemar MD, Saporito-Irwin SM, Sypherd PS, Fonzi WA: HWP1 functions in the morphological development of Candida albicans downstream of EFG1, TUP1, and RBF1. J. Bacteriol. 181, 5273-5279 (1999).
55. Lotz H, Sohn K, Brunner H, Muhlschlegel FA, Rupp S: RBR1, a novel pH-regulated cell wall gene of Candida albicans, is repressed by RIM101 and activated by NRG1. Eukaryot. Cell 3, 776-784 (2004).
56. Braun BR, Johnson AD: TUP1, CPH1 and EFG1 make independent contributions to filamentation in Candida albicans. Genetics 155, 57-67 (2000).
57. Nobile, CJ, Nett JE, Andes DR, Mitchell AP: Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryot. Cell 5, 1604-1610 (2006).
58. Nobile CJ, Mitchell AP: Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr. Biol. 15, 1150-1155 (2005).
59. Liu H: Co-regulation of pathogenesis with dimorphism and phenotypic switching in Candida albicans, a commensal and a pathogen. Int. J. Med. Microbiol. 292, 299-311 (2002).
60. Schweizer A, Rupp S, Taylor BN, Rollinghoff M, Schroppel K: The TEA/ATTS transcription factor CaTec1p regulates hyphal development and virulence in Candida albicans. Mol. Microbiol. 38, 435-445 (2000).
61. Sohn K, Senyurek I, Fertey J et al.: An in vitro assay to study the transcriptional response during adherence of Candida albicans to different human epithelia. FEMS Yeast Res. 6, 1085-1093 (2006).
62. Whiteway M, Oberholzer U: Candida morphogenesis and host-pathogen interactions. Curr. Opin. Microbiol. 7, 350-357 (2004).
63. Lorenz MC, Bender JA, Fink GR: Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryot. Cell 3, 1076-1087 (2004).
64. Rubin-Bejerano I, Fraser I, Grisafi P, Fink GR: Phagocytosis by neutrophils induces an amino acid deprivation response in Saccharomyces cerevisiae and Candida albicans. Proc. Natl Acad. Sci. USA 100, 11007-11012 (2003).
65. Fradin C, De Groot P, MacCallum D et al.: Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol. Microbiol. 56, 397-415 (2005).
66. de Repentigny L: Animal models in the analysis of Candida host-pathogen interactions. Curr. Opin. Microbiol. 7, 324-329 (2004).
67. Kretschmar M, Bertsch T, Goller M, Schaller M, Hof H, Nichterlein T: Parameters for determination of Candida albicans virulence in murine peritonitis. Mycoses 42 (Suppl. 2), 19-24 (1999).
68. Rozell B, Ljungdahl PO, Martinez P: Host-pathogen interactions and the pathological consequences of acute systemic Candida albicans infections in mice. Curr. Drug Targets 7, 483-494 (2006).
69. de Repentigny L, Aumont F, Ripeau JS et al.: Mucosal candidiasis in transgenic mice expressing human immunodeficiency virus type 1. J. Inlect. Dis. 185, 1103-1114 (2002).
70. Fidel PL Jr, Lynch ME, Sobel JD: Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect. Immun. 61, 1990-1995 (1993).
71. Dixon DM: In vivo models: evaluating antifungal agents. Methods Find. Exp. Clin. Pharmacol. 9, 729-738 (1987).
72. Louie A, Baltch AL, Franke MA et al.: Effect of pentoxifylline on the course of systemic Candida albicans infection in mice. J. Antimicrob. Chemother. 37, 943-954 (1996).
73. Andes D, Lepak A, Pitula A, Marchillo K, Clark J: A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site. J. Infect. Dis. 192, 893-900 (2005).
74. Lo HJ, Kohler JR, Di Domenico B, Loebenberg D, Cacciapuoti A, Fink GR: Nonfilamentous C. albicans mutants are avirulent. Cell 90, 939-949 (1997).
75. Muhlschlegel FA, Fonzi WA: PHR2 of Candida albicansn encodes a functional homolog of the pH-regulated gene PHR1 with an inverted pattern of pH-dependent expression. Mol. Cell Biol. 17, 5960-5967 (1997).
76. De Bernardis F, Muhlschlegel FA, Cassone A, Fonzi WA: The pH of the host niche controls gene expression in and virulence of Candida albicans. Infect. Immun. 66, 3317-3325 (1998).
77. Staib P, Kretschmar M, Nichterlein T et al.: Host-induced, stage-specific virulence gene activation in Candida albicans during infection. Mol. Microbiol. 32, 533-546 (1999).
78. Barelle CJ, Manson CL, MacCallum DM, Odds FC, Gow NA, Brown AJ: GFP as a quantitative reporter of gene regulation in Candida albicans. Yeast 21, 333-340 (2004).
79. Pitarch A, Diez-Orejas R, Molero G et al.: Analysis of the serologic response to systemic Candida albicans infection in a murine model. Proteomics 1, 550-559 (2001).
80. Pitarch A, Pardo M, Jimenez A, et al.: Two-dimensional gel electrophoresis as analytical tool for identifying Candida albicans immunogenic proteins. Electrophoresis 20, 1001-1010 (1999).
81. Fernandez-Arenas E, Molero G, Nombela C, Diez-Orejas R, Gil C: Contribution of the antibodies response induced by a low virulent Candida albicans strain in protection against systemic candidiasis. Proteomics 4, 1204-1215 (2004).
82. Bromuro C, Torosantucci A, Chiani P, Conti S, Polonelli L, Cassone A: Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70, 5462-5470 (2002).
83. Pitarch A, Abian J, Carrascal M, Sanchez M, Nombela C, Gil C: Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. Proteomics 4, 3084-3106 (2004).
84. Cheng S, Clancy CJ, Checkley MA et al.: Identification of Candida albicans genes induced during thrush offers insight into pathogenesis. Mol. Microbiol. 48, 1275-1288 (2003).
85. Swoboda RK, Bertram G, Hollander H et al.: Glycolytic enzymes of Candida albicans are nonubiquitous immunogens during candidiasis. Infect. Immun. 61, 4263-4271 (1993).
86. Naglik JR, Rodgers CA, Shirlaw PJ et al.: Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J. Infect. Dis. 188, 469-479 (2003).
87. Fidel PL Jr: Distinct protective host defenses against oral and vaginal candidiasis. Med. Mycol. 40, 359-375 (2002).
88. Spellberg BJ, Ibrahim AS, Avenissian V et al.: The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immucompromised mice. Infect. Immun. 73, 6191-6193 (2005).
89. Torosantucci A, Bromuro C, Chiani P et al.: A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597-606 (2005).
90. Raska M, Belakova J, Wudattu NK et al.: Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Folia Microbiol. (Praha) 50, 77-82 (2005).